SCHEMBL541977

SCHEMBL541977

CCn1c2c(c3cc(C#N)ccc31)CCC2

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RORC P51449 3/20 0.59
▸ SCARB1 Q8WTV0 4/20 0.58
▸ KDM4E B2RXH2 3/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ HTR6 P50406 2/20 0.45
▸ HRH1 P35367 1/20 0.45
▸ HSD17B10 Q99714 3/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ MAPT P10636 2/20 0.44
▸ HPGD P15428 2/20 0.44
▸ LMNA P02545 2/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ PTGER4 P35408 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ PPARG P37231 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ NCOA2 Q15596 1/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ USP14 P54578 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4023885 0.81 RORC (0.45) RORCSCARB1KDM4ERAB9AHTR6
SCHEMBL4194079 0.79 SCARB1 (0.67) RORCSCARB1HTR6HRH1CA1
SCHEMBL21076080 0.78 RORC (0.52) RORCKDM4EHSD17B10ALDH1A1MAPT
SCHEMBL14218042 0.77 HRH1 (0.60) RORCSCARB1HTR6HRH1CA1
SCHEMBL19271274 0.77 HSD17B10 (0.64) RORCKDM4ERAB9AHTR6HRH1
SCHEMBL4727325 0.75 MAPT (0.59) RORCKDM4ERAB9AHTR6HSD17B10
SCHEMBL15899412 0.75 HTR6 (0.57) RORCSCARB1KDM4ERAB9AHTR6
SCHEMBL13877230 0.75 BCHE (0.55) RORCKDM4ERAB9AHTR6HRH1
SCHEMBL14217953 0.75 SCARB1 (0.49) RORCSCARB1HTR6HRH1CA1
SCHEMBL13563272 0.75 SCARB1 (0.48) RORCSCARB1HTR6HRH1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1509518-B1 CALCIUM RECEPTOR MODULATING AGENTS AMGEN INC (US) 2012-02-08 — — EP disclosed
US-7176322-B2 Calcium receptor modulating agents AMGEN INC. (US) 2007-02-13 — — US disclosed
EP-1509518-A1 CALCIUM RECEPTOR MODULATING AGENTS Amgen, Inc. (US) 2005-03-02 — — EP disclosed
US-20040077619-A1 Calcium receptor modulating agents AMGEN INC. 2004-04-22 — — US disclosed
WO-2003099814-A1 CALCIUM RECEPTOR MODULATING AGENTS AMGEN, INC. (US) 2003-12-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077619-A1 Calcium receptor modulating agents PTH1R, CASR, CALCR RORC 1626/4885SCARB1 2757/4885KDM4E 3394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback